BY Linus Calov Jacobsen
-
Two lawsuits regarding competition violations hit Novo Nordisk in January
Novo Nordisk has actually been struck by 2 claims worrying competitors infractions this month, as mentioned in the business’s just recently released monetary record for 2025.
-
Novo Nordisk’s director in China steps down
Christine Zhou, that is the head of the China Area at Novo Nordisk, will certainly tip down at the end of March. A follower has actually been selected.
-
Genmab halts patient enrollment for cancer study acquired from Profoundbio acquisition
The study has been halted after just 23 patients. A few months ago, the company cancelled another potential drug acquired through the Profoundbio acquisition.
-
Eli Lilly estimates new approval date for weight loss pill
The American pharmaceutical huge revealed previously today that the tablet was anticipated to be authorized in the 2nd quarter.
